Ipamorelin: What the Research Actually Shows

Ipamorelin is a small lab-made peptide studied as a selective growth hormone secretagogue, which is a compound that nudges the body to release its own growth hormone. The honest headline is that the research is thin, mostly older and mostly preclinical, and we lay it out straight below.

A quick note on framing. Ipamorelin is not an approved drug for any use. We cite the studies below as research, not as a suggestion to use anything.

What researchers have studied

First characterization (Raun, European Journal of Endocrinology, 1998). The study that introduced ipamorelin. Working in cells and in animals, researchers reported that this five-amino-acid peptide triggered growth hormone release, and that unlike some related peptides it did not raise ACTH or cortisol beyond normal levels, even at doses more than 200 times the GH-releasing dose. Animal and in vitro model, not people. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/

Human pharmacokinetics (Gobburu, Pharmaceutical Research, 1999). A small study in healthy adult male volunteers. Researchers gave ipamorelin by infusion at rising doses and tracked both the peptide and growth hormone in the blood. They observed a single short pulse of growth hormone release and a short half-life of about 2 hours. Human model, but small and early. PMID 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/

Postoperative ileus trial (Beck, International Journal of Colorectal Disease, 2014). A randomized, placebo-controlled proof-of-concept trial in bowel-surgery patients, testing whether ipamorelin sped up the return of bowel function. Researchers found no statistically significant difference from placebo on the main measure (about 25 hours versus 33 hours to tolerate solid food). An honest negative result, and we include it because it is part of the record. PMID 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/

Trial registry record (ClinicalTrials.gov). The postoperative ileus study is registered as NCT00672074, with the protocol and outcome measures on file. https://clinicaltrials.gov/study/NCT00672074

How it works

Your body releases growth hormone in natural pulses from the pituitary gland. One of the switches that triggers those pulses is the ghrelin receptor.

Ipamorelin is built to bind that ghrelin receptor. In the studies above, that binding prompted the pituitary to put out a pulse of the body’s own growth hormone. Researchers call it “selective” because in the early animal work it nudged growth hormone without stirring up the stress hormones (ACTH and cortisol) that some related peptides also raise.

Like the GHRH-type compounds, it works upstream. It asks the gland to release growth hormone, rather than adding growth hormone from outside.

What the research does not establish

• The human data is thin. The main human study is a small, early pharmacokinetic look, and the one larger human trial (in bowel-surgery patients) did not beat placebo on its main goal.
• Most of the mechanism work is animal or in vitro, not people. Researchers have not established effects on muscle size, strength, body composition, or athletic performance in healthy adults.
• There is no approved human use. Ipamorelin is not an FDA-approved drug.
• Each finding describes a research model. It does not tell you what would happen in a person, and nothing here is a claim that this compound is safe to use.

For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Independent identity and purity testing by Janoshik. Nothing on this page is medical advice, a health claim, or a recommendation to use.